# This is a text dump done via copy & paste from the PDF of the 
# 17th WHO Model List of Essential Medicines (a95053_eng.pdf)
 
 
WHO Model List 
of 
Essential Medicines 
 
 
 
 
17th list 
(March 2011) 
 
 
 
 
Status of this document 
This is a reprint of the text on the WHO Medicines web site 
http://www.who.int/medicines/publications/essentialmedicines/en/index.html 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The published material is being distributed without warranty of any kind, either expressed or implied.  The 
responsibility for the interpretation and use of the material lies with the reader.  In no event shall the World Health 
Organization be liable for damages arising from its use. 
 
17th edition 
Essential Medicines 
WHO Model List (March 2011) 
Explanatory Notes 
 
The core list presents a list of minimum medicine needs for a basic health‐care system, listing the most 
efficacious, safe and cost‐effective medicines for priority conditions. Priority conditions are selected on the 
basis of current and estimated future public health relevance, and potential for safe and cost‐effective 
treatment. 
 
The complementary list presents essential medicines for priority diseases, for which specialized diagnostic 
or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt 
medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost‐
effectiveness in a variety of settings.  
 
The square box symbol ( ) is primarily intended to indicate similar clinical performance within a 
pharmacological class. The listed medicine should be the example of the class for which there is the best 
evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for 
marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there 
is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally 
available at the lowest price, based on international drug price information sources. Not all square boxes are 
applicable to medicine selection for children — see the second EMLc for details. 
 
Therapeutic equivalence is only indicated on the basis of reviews of efficacy and safety and when consistent 
with WHO clinical guidelines. National lists should not use a similar symbol and should be specific in their 
final selection, which would depend on local availability and price.  
 
The a symbol indicates that there is an age or weight restriction on use of the medicine; details for each 
medicine can be found in Table 1. 
 
Where the [c] symbol is placed next to the complementary list it signifies that the medicine(s) require(s) 
specialist diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training for 
their use in children. 
 
Where the [c] symbol is placed next to an individual medicine or strength of medicine it signifies that there 
is a specific indication for restricting its use to children. 
 
The presence of an entry on the Essential Medicines List carries no assurance as to pharmaceutical quality. It 
is the responsibility of the relevant national or regional drug regulatory authority to ensure that each 
product is of appropriate pharmaceutical quality (including stability) and that when relevant, different 
products are interchangeable. 
 
For recommendations and advice concerning all aspects of the quality assurance of medicines see the WHO 
Medicines web site http://www.who.int/medicines/areas/quality_assurance/en/index.html. 
 
Medicines and dosage forms are listed in alphabetical order within each section and there is no implication 
of preference for one form over another. Standard treatment guidelines should be consulted for information 
on appropriate dosage forms. 
 
 
The main terms used for dosage forms in the Essential Medicines List can be found in Annex 1. 
 
Definitions of many of these terms and pharmaceutical quality requirements applicable to the different 
categories are published in the current edition of The International Pharmacopoeia 
http://www.who.int/medicines/publications/pharmacopoeia/en/index.html. 
 
 
 
Essential Medicines 
WHO Model List 
17th edition 
1. ANAESTHETICS
1.1 General anaesthetics and oxygen
1.1.1 Inhalational medicines
halothane   Inhalation. 
isoflurane   Inhalation. 
nitrous oxide Inhalation. 
oxygen  Inhalation (medicinal gas).  
1.1.2 Injectable medicines 
ketamine 
Injection: 50 mg (as hydrochloride)/ml in 10‐ml vial. 
Injection: 10 mg/ml; 20 mg/ml. 
propofol* 
* Thiopental may be used as an alternative depending on local 
availability and cost. 
1.2 Local anaesthetics
Injection: 0.25%; 0.5% (hydrochloride) in vial.  
 bupivacaine 
Injection for spinal anaesthesia: 0.5% (hydrochloride) in 
4‐ml ampoule to be mixed with 7.5% glucose solution. 
Injection: 1%; 2% (hydrochloride) in vial. 
 lidocaine 
Injection for spinal anaesthesia: 5% (hydrochloride) in  
2‐ml ampoule to be mixed with 7.5% glucose solution. 
Topical forms: 2% to 4% (hydrochloride). 
Dental cartridge: 2% (hydrochloride) + epinephrine 1:80 000. 
lidocaine + epinephrine (adrenaline)  
Injection: 1%; 2% (hydrochloride or sulfate) + epinephrine 
1:200 000 in vial. 
Complementary List 
Injection: 30 mg (hydrochloride)/ml in 1‐ml ampoule. 
ephedrine 
(For use in spinal anaesthesia during delivery, to prevent hypotension). 
1.3 Preoperative medication and sedation for short-term procedures
atropine 
Injection: 1 mg (sulfate) in 1‐ml ampoule. 
Injection: 1 mg/ml. 
 midazolam 
Oral liquid: 2 mg/ml [c]. 
Tablet: 7.5 mg; 15 mg. 
morphine 
EML 17 (March 2011)
 
Injection: 10 mg (sulfate or hydrochloride) in 1‐ml ampoule. 
page - 1
Essential Medicines 
WHO Model List 
17th edition 
2. ANALGESICS, ANTIPYRETICS, NON-STEROIDAL ANTI-INFLAMMATORY
MEDICINES (NSAIMs), MEDICINES USED TO TREAT GOUT AND DISEASE MODIFYING
AGENTS IN RHEUMATOID DISORDERS (DMARDs)
2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
Suppository: 50 mg to 150 mg. 
acetylsalicylic acid 
Tablet: 100 mg to 500 mg. 
Oral liquid: 40 mg/ml (200 mg/5 ml). 
ibuprofen a  
Tablet: 200 mg; 400 mg. 
a
>3 months.
Oral liquid: 125 mg/5 ml. 
Suppository: 100 mg. 
paracetamol* 
Tablet: 100 mg to 500 mg. 
* Not recommended for anti‐inflammatory use due to lack of 
proven benefit to that effect. 
Complementary List [c] 
Suppository: 50 mg to 150 mg. 
acetylsalicylic acid* 
Tablet: 100 mg to 500 mg. 
* For use for rheumatic fever, juvenile arthritis, Kawasaki disease. 
2.2 Opioid analgesics
Tablet: 30 mg (phosphate). 
codeine* 
* The Expert Committee has requested a review of the 
comparative effectiveness and safety, for possible deletion of this 
medicine at its next meeting.  
Injection: 10 mg (morphine hydrochloride or morphine sulfate) 
in 1‐ml ampoule. 
morphine 
Oral liquid: 10 mg (morphine hydrochloride or morphine 
sulfate)/5 ml. 
Tablet: 10 mg (morphine sulfate). 
Tablet (prolonged release): 10 mg; 30 mg; 60 mg (morphine 
sulfate). 
2.3 Medicines used to treat gout
allopurinol 
Tablet: 100 mg. 
2.4 Disease modifying agents used in rheumatoid disorders (DMARDs)
Tablet: 100 mg; 150 mg (as phosphate or sulfate). 
chloroquine* 
EML 17 (March 2011)
 
* The Expert Committee has requested a review of the 
comparative effectiveness and safety, for possible deletion of this 
medicine at its next meeting. 
page - 2
Essential Medicines 
WHO Model List 
17th edition 
Complementary List
azathioprine  Tablet: 50 mg. 
hydroxychloroquine   Solid oral dosage form: 200 mg (as sulfate) [c]. 
methotrexate  Tablet: 2.5 mg (as sodium salt). 
penicillamine  Solid oral dosage form: 250 mg. 
sulfasalazine  Tablet: 500 mg. 
3. ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS
Injection: 10 mg (hydrogen maleate) in 1‐ml ampoule. 
 chlorphenamine a  
Oral liquid: 2 mg/5 ml (hydrogen maleate) [c]. 
Tablet: 4 mg (hydrogen maleate). 
a
>1 year. 
dexamethasone Injection: 4 mg dexamethasone phosphate (as disodium salt) in 
                      1‐ml ampoule. 
epinephrine (adrenaline) Injection: 1 mg (as hydrochloride or hydrogen tartrate) in  
                                   1‐ml ampoule. 
hydrocortisone Powder for injection: 100 mg (as sodium succinate) in vial. 
 prednisolone 
Oral liquid: 5 mg/ml [c]. 
Tablet: 5 mg; 25 mg. 
4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS
4.1 Non-specific
charcoal, activated 
Powder. 
4.2 Specific
Injection: 200 mg/ml in 10‐ml ampoule. 
acetylcysteine 
Oral liquid: 10% [c]; 20% [c]. 
atropine  Injection: 1 mg (sulfate) in 1‐ml ampoule. 
calcium gluconate  Injection: 100 mg/ml in 10‐ml ampoule. 
methylthioninium chloride   Injection: 10 mg/ml in 10‐ml ampoule. 
   (methylene blue)  
naloxone  Injection: 400 micrograms (hydrochloride) in 1‐ml ampoule. 
Solid oral dosage form: 250 mg. 
penicillamine* 
* The Expert Committee has requested a review of the 
comparative effectiveness and safety, for possible deletion of this 
medicine at its next meeting. 
potassium ferric hexacyano‐ferrate(II) ‐ Powder for oral administration. 
       2H20 (Prussian blue)  
sodium nitrite  Injection: 30 mg/ml in 10‐ml ampoule. 
EML 17 (March 2011)
 
page - 3
Essential Medicines 
WHO Model List 
sodium thiosulfate 
17th edition 
Injection: 250 mg/ml in 50‐ml ampoule. 
Complementary List 
deferoxamine  Powder for injection: 500 mg (mesilate) in vial. 
dimercaprol  Injection in oil: 50 mg/ml in 2‐ml ampoule. 
sodium calcium edetate   Injection: 200 mg/ml in 5‐ml ampoule. 
succimer  Solid oral dosage form: 100 mg. 
5. ANTICONVULSANTS/ANTIEPILEPTICS
Oral liquid: 100 mg/5 ml. 
carbamazepine 
Tablet (chewable): 100 mg; 200 mg. 
Tablet (scored): 100 mg; 200 mg. 
diazepam 
lorazepam 
Gel or rectal solution: 5 mg/ml in 0.5 ml; 2‐ml and 4‐ml tubes. 
Parenteral formulation: 2 mg/ml in 1‐ml ampoule; 4 mg/ml in  
1‐ml ampoule.  
Injection: 500 mg/ml in 2‐ml ampoule; 500 mg/ml in  
10‐ml ampoule. 
magnesium sulfate* 
* For use in eclampsia and severe pre‐eclampsia and not for other 
convulsant disorders. 
Injection: 200 mg/ml (phenobarbital sodium). 
phenobarbital  
Oral liquid: 15 mg/5 ml (phenobarbital). 
Tablet: 15 mg to 100 mg (phenobarbital). 
Capsule: 25 mg; 50 mg; 100 mg (sodium salt). 
Injection: 50 mg/ml in 5‐ml vial (sodium salt). 
Oral liquid: 25 mg to 30 mg/5 ml.* 
phenytoin 
Tablet: 25 mg; 50 mg; 100 mg (sodium salt). 
Tablet (chewable): 50 mg. 
* The presence of both 25 mg/5 ml and 30 mg/5 ml strengths on 
the same market would cause confusion in prescribing and 
dispensing and should be avoided. 
Oral liquid: 200 mg/5 ml. 
valproic acid (sodium valproate)  
Tablet (crushable): 100 mg. 
Tablet (enteric‐coated): 200 mg; 500 mg (sodium valproate). 
Complementary List 
Capsule: 250 mg. 
ethosuximide 
Oral liquid: 250 mg/5 ml. 
EML 17 (March 2011)
 
page - 4
Essential Medicines 
WHO Model List 
17th edition 
6. ANTI-INFECTIVE MEDICINES
6.1 Anthelminthics
6.1.1 Intestinal anthelminthics
albendazole 
Tablet (chewable): 400 mg. 
Tablet: 50 mg; 150 mg (as hydrochloride). 
levamisole* * The Expert Committee recommended that this medicine be 
                    reviewed for deletion at its next meeting. Should be used in 
                              combination with other anthleminthics. 
mebendazole  Tablet (chewable): 100 mg; 500 mg. 
Tablet (chewable): 500 mg. 
niclosamide*  * Niclosamide is listed for use when praziquantel treatment fails. 
                        The Expert Committee recommended that this medicine be 
                               reviewed for deletion at its next meeting. 
praziquantel  Tablet: 150 mg; 600 mg. 
Oral liquid: 50 mg (as embonate or pamoate)/ml. 
pyrantel 
Tablet (chewable): 250 mg (as embonate or pamoate). 
6.1.2 Antifilarials
albendazole  Tablet (chewable): 400 mg. 
diethylcarbamazine  Tablet: 50 mg; 100 mg (dihydrogen citrate). 
ivermectin  Tablet (scored): 3 mg; 6 mg. 
6.1.3 Antischistosomals and other antitrematode medicines 
praziquantel  Tablet: 600 mg. 
triclabendazole  Tablet: 250 mg. 
Complementary List 
Capsule: 250 mg. 
oxamniquine* 
Oral liquid: 250 mg/5 ml. 
* Oxamniquine is listed for use when praziquantel treatment fails. 
6.2 Antibacterials
6.2.1 Beta Lactam medicines
amoxicillin 
Powder for oral liquid: 125 mg (as trihydrate)/5 ml; 250 mg (as 
trihydrate)/5 ml [c]. 
Solid oral dosage form: 250 mg; 500 mg (as trihydrate). 
amoxicillin + clavulanic acid  
Oral liquid: 125 mg amoxicillin + 31.25 mg clavulanic acid/5 ml 
AND 250 mg amoxicillin + 62.5 mg clavulanic acid/5 ml [c]. 
Tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt). 
ampicillin 
EML 17 (March 2011)
 
Powder for injection: 500 mg; 1 g (as sodium salt) in vial. 
page - 5
Essential Medicines 
WHO Model List 
17th edition 
benzathine benzylpenicillin  Powder for injection: 900 mg benzylpenicillin (= 1.2 million IU) 
                                        in 5‐ml vial [c]; 1.44 g benzylpenicillin (= 2.4 million IU) in 5‐ml 
                                                        vial. 
benzylpenicillin  Powder for injection: 600 mg (= 1 million IU); 3 g (= 5 million IU) 
                                 (sodium or potassium salt) in vial. 
cefalexin [c]
Powder for reconstitution with water: 125 mg/5 ml; 250 mg/5 ml 
(anhydrous).  
Solid oral dosage form: 250 mg (as monohydrate). 
Powder for injection: 1 g (as sodium salt) in vial. 
cefazolin* a 
* For surgical prophylaxis. 
a
>1 month. 
Capsule: 400 mg (as trihydrate). 
cefixime* 
* Only listed for single‐dose treatment of uncomplicated ano‐
genital gonorrhoea. 
Powder for injection: 250 mg; 1 g (as sodium salt) in vial. 
ceftriaxone* a 
* Do not administer with calcium and avoid in infants with 
hyperbilirubinemia. 
a
>41 weeks corrected gestational age. 
Capsule: 500 mg; 1 g (as sodium salt). 
 cloxacillin 
Powder for injection: 500 mg (as sodium salt) in vial. 
Powder for oral liquid: 125 mg (as sodium salt)/5 ml. 
Powder for oral liquid: 250 mg (as potassium salt)/5 ml. 
phenoxymethylpenicillin 
Tablet: 250 mg (as potassium salt). 
Powder for injection: 1 g (=1 million IU); 3 g (=3 million IU) in 
vial.  
procaine benzylpenicillin* 
* Procaine benzylpenicillin is not recommended as first‐line 
treatment for neonatal sepsis except in settings with high 
neonatal mortality, when given by trained health workers in 
cases where hospital care is not achievable. 
Complementary List 
Powder for injection: 250 mg per vial (as sodium salt). 
cefotaxime* [c]   * 3rd generation cephalosporin of choice for use in hospitalized 
                              neonates. 
ceftazidime  Powder for injection: 250 mg or 1 g (as pentahydrate) in vial. 
EML 17 (March 2011)
 
page - 6
Essential Medicines 
WHO Model List 
17th edition 
Powder for injection: 250 mg (as monohydrate) + 250 mg (as sodium 
salt); 500 mg (as monohydrate) + 500 mg (as sodium salt) in vial. 
imipenem* + cilastatin*
* Only listed for the treatment of life‐threatening hospital‐based 
infection due to suspected or proven multidrug‐resistant infection. 
Meropenem is indicated for the treatment of meningitis and is licensed 
for use in children over the age of 3 months. 
6.2.2 Other antibacterials
Capsule: 250 mg; 500 mg (anhydrous). 
azithromycin* 
Oral liquid: 200 mg/5 ml. 
* Only listed for single‐dose treatment of genital Chlamydia 
trachomatis and of trachoma. 
Solid oral dosage form: 500 mg. 
clarithromycin* 
* For use in combination regimens for eradication of H. Pylori in 
adults. 
Capsule: 250 mg. 
Oily suspension for injection*: 0.5 g (as sodium succinate)/ml in 
2‐ml ampoule. 
chloramphenicol 
* Only for the presumptive treatment of epidemic meningitis in 
children older than 2 years. 
Oral liquid: 150 mg (as palmitate)/5 ml. 
Powder for injection: 1 g (sodium succinate) in vial. 
Oral liquid: 250 mg/5 ml (anhydrous) [c]. 
 ciprofloxacin 
Solution for IV infusion: 2 mg/ml (as hyclate) [c]. 
Tablet: 250 mg (as hydrochloride). 
Oral liquid: 25 mg/5 ml [c]; 50 mg/5 ml (anhydrous) [c]. 
doxycycline a 
Solid oral dosage form: 50 mg [c]; 100 mg (as hyclate).  
a Use in children <8 years only for life-threatening infections when no
alternative exists. 
Powder for injection: 500 mg (as lactobionate) in vial. 
 erythromycin 
Powder for oral liquid: 125 mg/5 ml (as stearate or estolate or 
ethyl succinate). 
Solid oral dosage form: 250 mg (as stearate or estolate or ethyl 
succinate). 
 gentamicin 
Injection: 10 mg; 40 mg (as sulfate)/ml in 2‐ml vial. 
Injection: 500 mg in 100‐ml vial. 
Oral liquid: 200 mg (as benzoate)/5 ml. 
 metronidazole 
Suppository: 500 mg; 1 g. 
Tablet: 200 mg to 500 mg. 
EML 17 (March 2011)
 
page - 7
Essential Medicines 
WHO Model List 
nitrofurantoin 
spectinomycin 
17th edition 
Oral liquid: 25 mg/5 ml [c]. 
Tablet: 100 mg. 
Powder for injection: 2 g (as hydrochloride) in vial. 
Injection:  
sulfamethoxazole + trimethoprim  
80 mg + 16 mg/ml in 5‐ml ampoule;  
80 mg + 16 mg/ml in 10‐ml ampoule. 
Oral liquid: 200 mg + 40 mg/5 ml. 
Tablet: 100 mg + 20 mg; 400 mg + 80 mg; 800 mg + 160 mg. 
Oral liquid: 50 mg/5 ml [c]. 
trimethoprim a  
Tablet: 100 mg; 200 mg. 
a
>6 months. 
Complementary List 
Capsule: 150 mg (as hydrochloride). 
clindamycin 
Injection: 150 mg (as phosphate)/ml. 
Oral liquid: 75 mg/5 ml (as palmitate) [c]. 
vancomycin 
Powder for injection: 250 mg (as hydrochloride) in vial. 
6.2.3 Antileprosy medicines 
Medicines  used  in  the  treatment  of  leprosy  should  never  be  used  except  in  combination.  Combination 
therapy is essential to prevent the emergence of drug resistance. Colour coded blister packs (MDT blister 
packs)  containing  standard  two  medicine  (paucibacillary  leprosy)  or  three  medicine  (multibacillary 
leprosy) combinations for adult and childhood leprosy should be used. MDT blister packs can be supplied 
free of charge through WHO. 
clofazimine  Capsule: 50 mg; 100 mg. 
dapsone  Tablet: 25 mg; 50 mg; 100 mg. 
rifampicin  Solid oral dosage form: 150 mg; 300 mg. 
6.2.4 Antituberculosis medicines
ethambutol 
ethambutol + isoniazid  
Oral liquid: 25 mg/ml [c]. 
Tablet: 100 mg to 400 mg (hydrochloride). 
Tablet: 400 mg + 150 mg. 
ethambutol + isoniazid + pyrazinamide 
Tablet: 275 mg + 75 mg + 400 mg + 150 mg. 
+ rifampicin  
ethambutol + isoniazid + rifampicin 
Tablet: 275 mg + 75 mg + 150 mg. 
Oral liquid: 50 mg/5 ml [c]. 
isoniazid 
Tablet: 100 mg to 300 mg. 
Tablet (scored): 50 mg.  
EML 17 (March 2011)
 
page - 8
Essential Medicines 
WHO Model List 
17th edition 
Tablet:  
isoniazid + pyrazinamide + rifampicin    75 mg + 400 mg + 150 mg. 
150 mg + 500 mg + 150 mg (For intermittent use three times 
weekly). 
Tablet:  
isoniazid + rifampicin  
75 mg + 150 mg; 150 mg + 300 mg. 
60 mg + 60 mg (For intermittent use three times weekly). 
150 mg + 150 mg (For intermittent use three times weekly). 
Oral liquid: 30 mg/ml [c]. 
Tablet: 400 mg. 
pyrazinamide 
Tablet (dispersible): 150 mg. 
Tablet (scored): 150 mg. 
Capsule: 150 mg.* 
rifabutin 
* For use only in patients with HIV receiving protease inhibitors.  
rifampicin 
Oral liquid: 20 mg/ml [c]. 
Solid oral dosage form: 150 mg; 300 mg. 
streptomycin 
Powder for injection: 1 g (as sulfate) in vial. 
Complementary List 
Reserve second‐line drugs for the treatment of multidrug‐resistant tuberculosis (MDR‐TB) should be 
used in specialized centres adhering to WHO standards for TB control.  
amikacin  Powder for injection: 100 mg; 500 mg; 1 g (as sulfate) in vial. 
capreomycin  Powder for injection: 1 g (as sulfate) in vial. 
cycloserine  Solid oral dosage form: 250 mg. 
ethionamide  Tablet: 125 mg; 250 mg. 
kanamycin  Powder for injection: 1 g (as sulfate) in vial. 
Tablet: 200 mg; 400 mg. 
ofloxacin* 
* Levofloxacin may be an alternative based on availability and 
programme considerations. 
Granules: 4 g in sachet. 
p‐aminosalicylic acid 
Tablet: 500 mg. 
6.3 Antifungal medicines 
Vaginal cream: 1%; 10%. 
clotrimazole 
Vaginal tablet: 100 mg; 500 mg. 
Capsule: 50 mg. 
 fluconazole 
Injection: 2 mg/ml in vial. 
Oral liquid: 50 mg/5 ml. 
EML 17 (March 2011)
 
page - 9
Essential Medicines 
WHO Model List 
17th edition 
Oral liquid: 125 mg/5 ml [c]. 
griseofulvin 
Solid oral dosage form: 125 mg; 250 mg. 
Lozenge: 100 000 IU. 
nystatin 
Oral liquid: 50 mg/5 ml [c]; 100 000 IU/ml [c]. 
Pessary: 100 000 IU. 
Tablet: 100 000 IU; 500 000 IU. 
Complementary List 
amphotericin B 
Powder for injection: 50 mg in vial. 
As sodium deoxycholate or liposomal complex. 
Capsule: 250 mg. 
flucytosine 
Infusion: 2.5 g in 250 ml. 
potassium iodide 
Saturated solution. 
6.4 Antiviral medicines
6.4.1 Antiherpes medicines
Oral liquid: 200 mg/5 ml [c]. 
 aciclovir 
Powder for injection: 250 mg (as sodium salt) in vial. 
Tablet: 200 mg. 
6.4.2 Antiretrovirals
Based on current evidence and experience of use, medicines in the following three classes of antiretrovirals 
are  included  as  essential  medicines  for  treatment  and  prevention  of  HIV  (prevention  of  mother‐to‐child 
transmission  and  post‐exposure  prophylaxis).  The  Committee  emphasizes  the  importance  of  using  these 
products  in  accordance  with  global  and  national  guidelines.    The  Committee  recommends  and  endorses 
the  use  of  fixed‐dose  combinations  and  the  development  of  appropriate  new  fixed‐dose  combinations, 
including  modified  dosage  forms,  non‐refrigerated  products  and  paediatric  dosage  forms  of  assured 
pharmaceutical quality. 
Scored tablets can be used in children and therefore can be considered for inclusion in the listing of tablets, 
provided adequate quality products are available. 
6.4.2.1 Nucleoside/Nucleotide reverse transcriptase inhibitors 
Oral liquid: 100 mg (as sulfate)/5 ml. 
abacavir (ABC) 
Tablet: 300 mg (as sulfate). 
Buffered powder for oral liquid: 100 mg; 167 mg; 250 mg packets. 
didanosine (ddI) 
Capsule (unbuffered enteric‐coated): 125 mg; 200 mg; 250 mg; 
400 mg. 
Tablet (buffered chewable, dispersible): 25 mg; 50 mg; 100 mg; 
150 mg; 200 mg. 
EML 17 (March 2011)
 
page - 10
Essential Medicines 
WHO Model List 
17th edition 
Capsule: 200 mg. 
Oral liquid: 10 mg/ml. 
emtricitabine (FTC)* a 
* FTC is an acceptable alternative to 3TC, based on knowledge of 
the pharmacology, the resistance patterns and clinical trials of 
antiretrovirals. 
a
>3 months. 
Oral liquid: 50 mg/5 ml. 
lamivudine (3TC) 
Tablet: 150 mg. 
Capsule: 15 mg; 20 mg; 30 mg. 
stavudine (d4T) 
Powder for oral liquid: 5 mg/5 ml. 
tenofovir disoproxil fumarate (TDF) 
Tablet: 300 mg (tenofovir disoproxil fumarate – equivalent to  
245 mg tenofovir disoproxil). 
Capsule: 100 mg; 250 mg. 
Oral liquid: 50 mg/5 ml. 
zidovudine (ZDV or AZT) 
Solution for IV infusion injection: 10 mg/ml in 20‐ml vial. 
Tablet: 300 mg. 
6.4.2.2 Non-nucleoside reverse transcriptase inhibitors 
Capsule: 50 mg; 100 mg; 200 mg. 
Oral liquid: 150 mg/5 ml. 
efavirenz (EFV or EFZ) a  
Tablet: 600 mg. 
a
>3 years or >10 kg weight. 
Oral liquid: 50 mg/5 ml. 
nevirapine (NVP) 
Tablet: 200 mg. 
6.4.2.3 Protease inhibitors 
Selection  of  protease  inhibitor(s)  from  the  Model  List  will  need  to  be  determined  by  each  country  after 
consideration of international and national treatment guidelines and experience. Ritonavir is recommended 
for use in combination as a pharmacological booster, and not as an antiretroviral in its own right. All other 
protease inhibitors should be used in boosted forms (e.g. with ritonavir). 
Solid oral dosage form: 100 mg; 150 mg; 300 mg (as sulfate). 
atazanavir a 
indinavir (IDV) 
a
>25 kg.  
Solid oral dosage form: 400 mg (as sulfate). 
Capsule: 133.3 mg + 33.3 mg.  
lopinavir + ritonavir (LPV/r)  
Oral liquid: 400 mg + 100 mg/5 ml. 
Tablet (heat stable): 100 mg + 25 mg; 200 mg + 50 mg. 
EML 17 (March 2011)
 
page - 11
Essential Medicines 
WHO Model List 
17th edition 
Oral liquid: 400 mg/5 ml. 
ritonavir 
Solid oral dosage form: 100 mg. 
Tablet (heat stable): 25 mg; 100 mg.  
Solid oral dosage form: 200 mg; 500 mg (as mesilate). 
saquinavir (SQV) a  
a
>25 kg. 
FIXED-DOSE COMBINATIONS 
Tablet: 600 mg + 200 mg + 300 mg (disoproxil fumarate equivalent 
to 245 mg tenofovir disoproxil). 
efavirenz + emtricitabine* + tenofovir  
* FTC is an acceptable alternative to 3TC, based on knowledge of 
the pharmacology, the resistance patterns and clinical trials of 
antiretrovirals. 
Tablet: 200 mg + 300 mg (disoproxil fumarate equivalent to 
245 mg tenofovir disoproxil). 
emtricitabine* + tenofovir  
* FTC is an acceptable alternative to 3TC, based on knowledge of 
the pharmacology, the resistance patterns and clinical trials of 
antiretrovirals. 
Tablet: 150 mg + 200 mg + 30 mg. 
lamivudine + nevirapine + stavudine  
Tablet (dispersible):  
30 mg + 50 mg + 6 mg [c]; 60 mg + 100 mg + 12 mg [c]. 
 
lamivudine + nevirapine +  Tablet: 30 mg + 50 mg + 60 mg [c]; 150 mg + 200 mg + 300 mg. 
    zidovudine   
lamivudine + zidovudine  Tablet: 30 mg + 60 mg [c]; 150 mg + 300 mg. 
6.4.3 Other antivirals 
Capsule: 30 mg; 45 mg; 75 mg (as phosphate). 
Oral powder: 12 mg/ml. 
oseltamivir*   
* Oseltamivir should be used only in compliance with the WHO 
treatment guidelines, i.e. (1) for treatment of patients with severe 
or progressive clinical illness with confirmed or suspected 
influenza pandemic (H1N1) 2009, (2) for the treatment of patients 
with confirmed or suspected but uncomplicated illness due to 
pandemic influenza virus infection who were in higher risk 
groups, most notably for pregnant women and children under 
2 years of age. 
Injection for intravenous administration: 800 mg and 1 g in 10‐ml 
phosphate buffer solution. 
ribavirin*  
Solid oral dosage form: 200 mg; 400 mg; 600 mg. 
* For the treatment of viral haemorrhagic fevers only. 
 
 
 
EML 17 (March 2011)
 
page - 12
Essential Medicines 
WHO Model List 
17th edition 
6.5 Antiprotozoal medicines 
6.5.1 Antiamoebic and antigiardiasis medicines 
diloxanide a  
Tablet: 500 mg (furoate). 
a
>25 kg.
Injection: 500 mg in 100‐ml vial. 
 metronidazole 
Oral liquid: 200 mg (as benzoate)/5 ml. 
Tablet: 200 mg to 500 mg. 
6.5.2 Antileishmaniasis medicines 
amphotericin B 
Powder for injection: 50 mg in vial. 
As sodium deoxycholate or liposomal complex. 
miltefosine  Solid oral dosage form: 10 mg; 50 mg. 
paromomycin Solution for intramuscular injection: 750 mg of paromomycin 
                   base (as the sulfate). 
                      Injection: 100 mg/ml, 1 vial = 30 ml or 30%, equivalent to 
                                 approximately 8.1% antimony (pentavalent) in 5‐ml ampoule.  
sodium stibogluconate or meglumine 
antimoniate 
6.5.3 Antimalarial medicines
6.5.3.1 For curative treatment
Medicines for the treatment of P. falciparum malaria cases should be used in combination.  The list currently 
recommends  combinations  according  to  treatment  guidelines.    The  Committee  recognizes  that  not  all  of 
these FDCs exist and encourages their development and rigorous testing.  The Committee also encourages 
development and testing of rectal dosage formulations. 
Tablet: 153 mg or 200 mg (as hydrochloride). 
amodiaquine* 
* To be used in combination with artesunate 50 mg. 
Oily injection: 80 mg/ml in 1‐ml ampoule. 
artemether* 
* For use in the management of severe malaria. 
Tablet: 20 mg + 120 mg. 
artemether + lumefantrine* 
Tablet (dispersible): 20 mg + 120 mg [c]. 
* Not recommended in the first trimester of pregnancy or in 
children below 5 kg. 
Injection: ampoules, containing 60 mg anhydrous artesunic acid 
with a separate ampoule of 5% sodium bicarbonate solution. 
For use in the management of severe malaria. 
artesunate* 
Rectal dosage form: 50 mg [c]; 200 mg capsules (for pre‐referral 
treatment of severe malaria only; patients should be taken to an 
appropriate health facility for follow‐up care) [c]. 
Tablet: 50 mg. 
* To be used in combination with either amodiaquine, mefloquine 
or sulfadoxine + pyrimethamine. 
EML 17 (March 2011)
 
page - 13
Essential Medicines 
WHO Model List 
17th edition 
Tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg. 
artesunate + amodiaquine *  * Other combinations that deliver the target doses required such as 
                                          153 mg or 200 mg (as hydrochloride) with 50 mg artesunate can be 
                                                      alternatives. 
                                                      Oral liquid: 50 mg (as phosphate or sulfate)/5 ml. 
chloroquine*  Tablet: 100 mg; 150 mg (as phosphate or sulfate). 
* For use only for the treatment of P.vivax infection. 
Capsule: 100 mg (as hydrochloride or hyclate). 
doxycycline* 
Tablet (dispersible): 100 mg (as monohydrate). 
* For use only in combination with quinine. 
Tablet: 250 mg (as hydrochloride).  
mefloquine* 
* To be used in combination with artesunate 50 mg. 
Tablet: 7.5 mg; 15 mg (as diphosphate). 
primaquine* 
* Only for use to achieve radical cure of P.vivax and P.ovale 
infections, given for 14 days. 
Injection: 300 mg quinine hydrochloride/ml in 2‐ml ampoule. 
quinine* 
Tablet: 300 mg (quinine sulfate) or 300 mg (quinine bisulfate). 
* For use only in the management of severe malaria, and should be 
used in combination with doxycycline. 
Tablet: 500 mg + 25 mg. 
sulfadoxine + pyrimethamine* 
* Only in combination with artesunate 50 mg. 
6.5.3.2 For prophylaxis 
Oral liquid: 50 mg (as phosphate or sulfate)/5 ml. 
chloroquine* 
Tablet: 150 mg (as phosphate or sulfate). 
* For use only in central American regions, for use for P.vivax. 
Solid oral dosage form: 100 mg (as hydrochloride or hyclate). 
doxycycline a  
a
>8 years. 
Tablet: 250 mg (as hydrochloride). 
mefloquine a  
a
>5 kg or >3 months. 
Tablet: 100 mg (as hydrochloride). 
proguanil* 
* For use only in combination with chloroquine. 
6.5.4 Antipneumocystosis and antitoxoplasmosis medicines 
pyrimethamine  Tablet: 25 mg. 
sulfadiazine  Tablet: 500 mg. 
EML 17 (March 2011)
 
page - 14
Essential Medicines 
WHO Model List 
17th edition 
Injection:  
sulfamethoxazole + trimethoprim 
80 mg + 16 mg/ml in 5‐ml ampoule;  
80 mg + 16 mg/ml in 10‐ml ampoule. 
Oral liquid: 200 mg + 40 mg/5 ml [c]. 
Tablet: 100 mg + 20 mg; 400 mg + 80 mg [c]. 
Complementary List
pentamidine 
Tablet: 200 mg; 300 mg (as isethionate). 
6.5.5 Antitrypanosomal medicines 
6.5.5.1 African trypanosomiasis 
Medicines for the treatment of 1st stage African trypanosomiasis 
Powder for injection: 200 mg (as isetionate) in vial. 
pentamidine* 
* To be used for the treatment of Trypanosoma brucei gambiense 
infection. 
Powder for injection: 1 g in vial. 
suramin sodium* 
* To be used for the treatment of the initial phase of 
Trypanosoma brucei rhodesiense infection. 
Medicines for the treatment of 2nd stage African trypanosomiasis 
Injection: 200 mg (hydrochloride)/ml in 100‐ml bottle. 
eflornithine* 
melarsoprol 
nifurtimox* 
* To be used for the treatment of Trypanosoma brucei gambiense 
infection. 
Injection: 3.6% solution, 5‐ml ampoule (180 mg of active  
compound). 
Tablet: 120 mg. 
* Only to be used in combination with eflornithine, for  the 
treatment of Trypanosoma brucei gambiense infection. 
Complementary List [c] 
melarsoprol 
Injection: 3.6% solution in 5‐ml ampoule (180 mg of active compound). 
6.5.5.2 American trypanosomiasis 
benznidazole  Tablet: 100 mg. 
nifurtimox  Tablet: 30 mg; 120 mg; 250 mg. 
7. ANTIMIGRAINE MEDICINES 
7.1 For treatment of acute attack 
acetylsalicylic acid  Tablet: 300 mg to 500 mg. 
ibuprofen [c]  Tablet: 200 mg; 400 mg. 
paracetamol 
Oral liquid: 125 mg/5 ml [c]. 
Tablet: 300 mg to 500 mg. 
 
EML 17 (March 2011)
 
page - 15
Essential Medicines 
WHO Model List 
17th edition 
7.2 For prophylaxis
 propranolol 
Tablet: 20 mg; 40 mg (hydrochloride). 
8. ANTINEOPLASTIC, IMMUNOSUPPRESSIVES AND MEDICINES USED IN
PALLIATIVE CARE
8.1 Immunosuppressive medicines
Complementary List 
Powder for injection: 100 mg (as sodium salt) in vial. 
azathioprine
Tablet (scored): 50 mg. 
Capsule: 25 mg. 
ciclosporin
Concentrate for injection: 50 mg/ml in 1‐ml ampoule for organ 
transplantation. 
8.2 Cytotoxic and adjuvant medicines  
Complementary List 
allopurinol [c]  Solid oral dosage form: 100 mg; 300 mg. 
asparaginase  Powder for injection: 10 000 IU in vial. 
bleomycin  Powder for injection: 15 mg (as sulfate) in vial. 
Injection: 3 mg/ml in 10‐ml ampoule. 
calcium folinate 
Tablet: 15 mg. 
carboplatin 
chlorambucil 
Injection: 50 mg/5 ml; 150 mg/15 ml; 450 mg/45 ml; 600 mg/60 ml. 
Tablet: 2 mg. 
Powder for injection: 500 mg in vial. 
cyclophosphamide 
Tablet: 25 mg. 
cytarabine  Powder for injection: 100 mg in vial. 
dacarbazine  Powder for injection: 100 mg in vial. 
dactinomycin  Powder for injection: 500 micrograms in vial. 
daunorubicin  Powder for injection: 50 mg (hydrochloride) in vial. 
docetaxel  Injection: 20 mg/ml; 40 mg/ml. 
doxorubicin  Powder for injection: 10 mg; 50 mg (hydrochloride) in vial. 
Capsule: 100 mg. 
etoposide 
Injection: 20 mg/ml in 5‐ml ampoule. 
fluorouracil  Injection: 50 mg/ml in 5‐ml ampoule. 
hydroxycarbamide  Solid oral dosage form: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 
                                1 g. 
ifosfamide  Powder for injection: 1 g vial; 2 g vial. 
mercaptopurine  Tablet: 50 mg. 
EML 17 (March 2011)
 
page - 16
Essential Medicines 
WHO Model List 
17th edition 
Injection: 100 mg/ml in 4‐ml and 10‐ml ampoules. 
mesna 
Solid oral dosage form: 400 mg; 600 mg. 
Powder for injection: 50 mg (as sodium salt) in vial. 
methotrexate 
Tablet: 2.5 mg (as sodium salt). 
paclitaxel  Powder for injection: 6 mg/ml. 
procarbazine  Capsule: 50 mg (as hydrochloride). 
thioguanine [c]  Solid oral dosage form: 40 mg. 
vinblastine  Powder for injection: 10 mg (sulfate) in vial. 
vincristine  Powder for injection: 1 mg; 5 mg (sulfate) in vial. 
8.3 Hormones and antihormones 
Complementary List 
dexamethasone 
Injection: 4 mg dexamethasone phosphate (as disodium salt) in  
1‐ml ampoule. 
Oral liquid: 2 mg/5 ml [c]. 
hydrocortisone  Powder for injection: 100 mg (as sodium succinate) in vial. 
methylprednisolone [c]  Injection: 40 mg/ml (as sodium succinate) in 1‐ml single dose vial and  
                                        5‐ml multidose vials; 80 mg/ml (as sodium succinate) in 1‐ml single dose 
                                                       vial. 
Oral liquid: 5 mg/ml [c]. 
 prednisolone 
Tablet: 5 mg; 25 mg. 
tamoxifen 
Tablet: 10 mg; 20 mg (as citrate). 
8.4 Medicines used in palliative care
The WHO Expert Committee recognizes the importance of listing specific medicines in the Palliative Care 
Section.  Some medicines currently used in palliative care are included in the relevant sections of the Model 
List,  according  to  their  therapeutic  use,  e.g.  analgesics.    The  Guidelines  for  Palliative  Care  that  were 
referenced  in  the  previous  list  are  in  need  of  update.    The  Committee  expects  applications  for  medicines 
needed for palliative care to be submitted for the next meeting.  
amitriptyline [c] 
cyclizine [c] 
dexamethasone [c] 
Tablet: 10 mg; 25 mg. 
Injection: 50 mg/ml. 
Tablet: 50 mg. 
Injection: 4 mg/ml. 
Tablet: 2 mg. 
Injection: 5 mg/ml. 
diazepam [c] 
Oral liquid: 2 mg/5 ml. 
Rectal solution: 2.5 mg; 5 mg; 10 mg. 
Tablet: 5 mg; 10 mg. 
EML 17 (March 2011)
 
page - 17
Essential Medicines 
WHO Model List 
docusate sodium [c]  
fluoxetine a [c]  
hyoscine hydrobromide [c] 
17th edition 
Capsule: 100 mg.  
Oral liquid: 50 mg/5 ml. 
Solid oral dosage form: 20 mg (as hydrochloride). 
a
>8 years. 
Injection: 400 micrograms/ml; 600 micrograms/ml. 
Transdermal patches: 1 mg/72 hours. 
Oral liquid: 100 mg/5 ml. 
ibuprofen a [c] 
Tablet: 200 mg; 400 mg; 600 mg. 
a
Not in children less than 3 months.
lactulose [c]  Oral liquid: 3.1‐3.7 g/5 ml. 
midazolam [c]  Injection: 1 mg/ml; 5 mg/ml. 
Granules (modified release) (to mix with water): 20 mg; 30 mg; 
60 mg; 100 mg; 200 mg. 
Injection: 10 mg/ml. 
morphine [c] 
Oral liquid: 10 mg/5 ml. 
Tablet (controlled release): 10 mg; 30 mg; 60 mg.  
Tablet (immediate release): 10 mg. 
Injection: 2 mg base/ml in 2‐ml ampoule (as hydrochloride). 
ondansetron [c] a 
Oral liquid: 4 mg base/ 5 ml. 
Solid oral dosage form: Eq 4 mg base; Eq 8 mg base. 
a
senna [c] 
>1 month. 
Oral liquid: 7.5 mg/5 ml.  
9. ANTIPARKINSONISM MEDICINES 
Injection: 5 mg (lactate) in 1‐ml ampoule. 
biperiden 
Tablet: 2 mg (hydrochloride). 
levodopa +   carbidopa  
Tablet: 100 mg + 10 mg; 250 mg + 25 mg. 
10. MEDICINES AFFECTING THE BLOOD 
10.1 Antianaemia medicines 
Oral liquid: equivalent to 25 mg iron (as sulfate)/ml. 
ferrous salt 
Tablet: equivalent to 60 mg iron. 
ferrous salt + folic acid   Tablet equivalent to 60 mg iron + 400 micrograms folic acid 
                                            (Nutritional supplement for use during pregnancy). 
folic acid  Tablet: 1 mg; 5 mg. 
hydroxocobalamin  Injection: 1 mg (as acetate, hydrochloride or as sulfate) in 1‐ml 
                               ampoule. 
 
EML 17 (March 2011)
 
page - 18
Essential Medicines 
WHO Model List 
17th edition 
10.2 Medicines affecting coagulation 
heparin sodium 
Injection: 1000 IU/ml; 5000 IU/ml; 20 000 IU/ml in 1‐ml ampoule. 
Injection: 1 mg/ml [c]; 10 mg/ml in 5‐ml ampoule. 
phytomenadione 
Tablet: 10 mg. 
protamine sulfate  Injection: 10 mg/ml in 5‐ml ampoule. 
tranexamic acid  Injection: 100 mg/ml in 10‐ml ampoule. 
 warfarin 
Tablet: 1 mg; 2 mg; 5 mg (sodium salt). 
Complementary List [c] 
heparin sodium   Injection: 1000 IU/ml; 5000 IU/ml in 1‐ml ampoule. 
protamine sulfate   Injection: 10 mg/ml in 5‐ml ampoule. 
 warfarin  
Tablet: 0.5 mg; 1 mg; 2 mg; 5 mg (sodium salt). 
10.3 Other medicines for haemoglobinopathies
Complementary List 
deferoxamine*  Powder for injection: 500 mg (mesilate) in vial. 
                       * Deferasirox oral form may be an alternative, depending on cost and 
                                  availability. 
hydroxycarbamide  Solid oral dosage form: 200 mg; 500 mg; 1 g. 
11. BLOOD PRODUCTS AND PLASMA SUBSTITUTES
11.1 Plasma substitutes
Injectable solution: 6%. 
 dextran 70* 
* Polygeline, injectable solution, 3.5% is considered as equivalent. 
11.2 Plasma fractions for specific use
All  plasma  fractions  should  comply  with  the  WHO  Requirements  for  the  Collection,  Processing  and 
Quality  Control  of  Blood,  Blood  Components  and  Plasma  Derivatives  (Revised  1992).  (WHO  Technical 
Report Series, No. 840, 1994, Annex 2). 
Complementary List 
 factor VIII concentrate 
 factor IX complex (coagulation 
factors, II, VII, IX, X) concentrate 
Dried. 
Dried. 
Intramuscular administration: 16% protein solution.* 
Intravenous administration: 5%; 10% protein solution.** 
human normal immunoglobulin 
Subcutaneous administration: 15%; 16% protein solution.*  
*   Indicated for primary immune deficiency. 
** Indicated for primary immune deficiency and Kawasaki disease. 
EML 17 (March 2011)
 
page - 19
Essential Medicines 
WHO Model List 
17th edition 
12. CARDIOVASCULAR MEDICINES
12.1 Antianginal medicines
Tablet: 1.25 mg; 5 mg. 
 bisoprolol* 
*   includes metoprolol and carvedilol as alternatives. 
glyceryl trinitrate
 isosorbide dinitrate 
verapamil 
Tablet (sublingual): 500 micrograms. 
Tablet (sublingual): 5 mg. 
Tablet: 40 mg; 80 mg (hydrochloride). 
12.2 Antiarrhythmic medicines
Tablet: 1.25 mg; 5 mg. 
 bisoprolol* 
*   includes metoprolol and carvedilol as alternatives. 
Injection: 250 micrograms/ml in 2‐ml ampoule. 
digoxin 
Oral liquid: 50 micrograms/ml. 
Tablet: 62.5 micrograms; 250 micrograms. 
epinephrine (adrenaline)  Injection: 100 micrograms/ml (as acid tartrate or hydrochloride) in 
                                    10‐ml ampoule. 
lidocaine  Injection: 20 mg (hydrochloride)/ml in 5‐ml ampoule. 
Injection: 2.5 mg (hydrochloride)/ml in 2‐ml ampoule. 
verapamil 
Tablet: 40 mg; 80 mg (hydrochloride). 
Complementary List 
Injection: 50 mg/ml in 3‐ml ampoule (hydrochloride). 
amiodarone 
Tablet (HCI): 100 mg; 200 mg; 400 mg (hydrochloride). 
12.3 Antihypertensive medicines
 amlodipine 
Tablet: 5 mg (as maleate, mesylate or as besylate). 
Tablet: 1.25 mg; 5 mg. 
 bisoprolol* 
*   includes metoprolol and carvedilol as alternatives. 
 enalapril 
Tablet: 2.5 mg; 5 mg (as hydrogen maleate). 
Powder for injection: 20 mg (hydrochloride) in ampoule. 
Tablet: 25 mg; 50 mg (hydrochloride). 
hydralazine* 
* Hydralazine is listed for use in the acute management of severe 
pregnancy‐induced hypertension only. Its use in the treatment of 
essential hypertension is not recommended in view of the 
availability of more evidence of efficacy and safety of other 
medicines. 
Oral liquid: 50 mg/5 ml. 
 hydrochlorothiazide 
Solid oral dosage form: 12.5 mg; 25 mg. 
EML 17 (March 2011)
 
page - 20
Essential Medicines 
WHO Model List 
17th edition 
Tablet: 250 mg. 
methyldopa*
* Methyldopa is listed for use in the management of pregnancy‐
induced hypertension only. Its use in the treatment of essential 
hypertension is not recommended in view of the availability of 
more evidence of efficacy and safety of other medicines. 
Complementary List 
sodium nitroprusside
Powder for infusion: 50 mg in ampoule. 
12.4 Medicines used in heart failure
Tablet: 1.25 mg; 5 mg. 
 bisoprolol* 
*  includes metoprolol and carvedilol as alternatives. 
Injection: 250 micrograms/ml in 2‐ml ampoule. 
digoxin
Oral liquid: 50 micrograms/ml. 
Tablet: 62.5 micrograms; 250 micrograms. 
 enalapril
Tablet: 2.5 mg; 5 mg (as hydrogen maleate). 
Injection: 10 mg/ml in 2‐ml ampoule. 
 furosemide
Oral liquid: 20 mg/5 ml [c]. 
Tablet: 40 mg. 
Oral liquid: 50 mg/5 ml. 
 hydrochlorothiazide
Solid oral dosage form: 25 mg. 
Complementary List 
dopamine
Injection: 40 mg/ml (hydrochloride) in 5‐ml vial. 
12.5 Antithrombotic medicines
acetylsalicylic acid
Tablet: 100 mg. 
Complementary List 
streptokinase 
Powder for injection: 1.5 million IU in vial. 
12.6 Lipid-lowering agents
Tablet: 5 mg; 10 mg; 20 mg; 40 mg. 
 simvastatin* 
* For use in high‐risk patients. 
13. DERMATOLOGICAL MEDICINES (topical)
13.1 Antifungal medicines
 miconazole  Cream or ointment: 2% (nitrate). 
selenium sulfide  Detergent‐based suspension: 2%. 
sodium thiosulfate  Solution: 15%. 
terbinafine  Cream: 1% or Ointment: 1% terbinafine hydrochloride. 
EML 17 (March 2011)
 
page - 21
Essential Medicines 
WHO Model List 
17th edition 
13.2 Anti-infective medicines
Cream (as mupirocin calcium): 2%. 
mupirocin 
Ointment: 2%. 
potassium permanganate 
Aqueous solution: 1:10 000. 
Cream: 1%. 
silver sulfadiazine a  
a
>2 months. 
13.3 Anti-inflammatory and antipruritic medicines
Cream or ointment: 0.1% (as valerate). 
 betamethasone a  
a
Hydrocortisone preferred in neonates. 
 calamine   Lotion. 
 hydrocortisone  Cream or ointment: 1% (acetate). 
13.4 Medicines affecting skin differentiation and proliferation
benzoyl peroxide Cream or lotion: 5%. 
coal tar  Solution: 5%. 
Ointment: 0.1% to 2%.   
dithranol*  * The Expert Committee has requested a review of the 
                      comparative effectiveness and safety, for possible deletion of this 
                              medicine at its next meeting. 
fluorouracil  Ointment: 5%. 
 podophyllum resin 
Solution: 10% to 25%. 
salicylic acid Solution: 5%. 
urea Cream or ointment: 5%; 10%. 
13.5 Scabicides and pediculicides
 benzyl benzoate a  
Lotion: 25%. 
a
>2 years.
Cream: 5%. 
permethrin 
Lotion: 1%. 
14. DIAGNOSTIC AGENTS
14.1 Ophthalmic medicines
fluorescein 
 tropicamide 
Eye drops: 1% (sodium salt). 
Eye drops: 0.5%. 
14.2 Radiocontrast media
 amidotrizoate
barium sulfate
EML 17 (March 2011)
 
Injection: 140 mg to 420 mg iodine (as sodium or meglumine 
salt)/ml in 20‐ml ampoule. 
Aqueous suspension. 
page - 22
Essential Medicines 
WHO Model List 
 iohexol
17th edition 
Injection: 140 mg to 350 mg iodine/ml in 5‐ml; 10‐ml; 20‐ml 
ampoules. 
Complementary List 
barium sulfate [c] 
 meglumine iotroxate
Aqueous suspension. 
Solution: 5 g to 8 g iodine in 100 ml to 250 ml. 
15. DISINFECTANTS AND ANTISEPTICS
15.1 Antiseptics
 chlorhexidine  Solution: 5% (digluconate); 20% (digluconate) (needs to be diluted 
                          prior to use for cord care) [c]. 
 ethanol  Solution: 70% (denatured). 
 polyvidone iodine  Solution: 10% (equivalent to 1% available iodine). 
15.2 Disinfectants
 chlorine base compound Powder: (0.1% available chlorine) for solution. 
 chloroxylenol Solution: 4.8%. 
Solution: 2%. 
glutaral
16. DIURETICS
amiloride
Tablet: 5 mg (hydrochloride). 
Injection: 10 mg/ml in 2‐ml ampoule. 
 furosemide
Oral liquid: 20 mg/5 ml [c]. 
Tablet: 10 mg [c]; 20 mg [c]; 40 mg. 
 hydrochlorothiazide
Solid oral dosage form: 25 mg. 
mannitol Injectable solution: 10%; 20%. 
spironolactone Tablet: 25 mg. 
Complementary List [c] 
 hydrochlorothiazide
mannitol 
spironolactone 
Tablet (scored): 25 mg. 
Injectable solution: 10%; 20%.
Oral liquid: 5 mg/5 ml; 10 mg/5 ml; 25 mg/5 ml. 
Tablet: 25 mg.
17. GASTROINTESTINAL MEDICINES
Complementary List [c] 
 pancreatic enzymes
Age‐appropriate formulations and doses including lipase, protease and 
amylase. 
 
 
 
 
EML 17 (March 2011)
 
page - 23
Essential Medicines 
WHO Model List 
17th edition 
17.1 Antiulcer medicines 
 omeprazole
Powder for oral liquid: 20 mg; 40 mg sachets. 
Solid oral dosage form: 10 mg; 20 mg; 40 mg. 
Injection: 25 mg/ml (as hydrochloride) in 2‐ml ampoule. 
Oral liquid: 75 mg/5 ml (as hydrochloride). 
 ranitidine* 
Tablet: 150 mg (as hydrochloride). 
* The Expert Committee has requested a review of the 
comparative effectiveness and safety, for possible deletion of this 
class of medicine at its next meeting. 
17.2 Antiemetic medicines
Injection: 4 mg/ml in 1‐ml ampoule (as disodium phosphate salt). 
dexamethasone 
Oral liquid: 0.5 mg/5 ml; 2 mg/5 ml. 
Solid oral dosage form: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg. 
Injection: 5 mg (hydrochloride)/ml in 2‐ml ampoule. 
metoclopramide a  
Oral liquid: 5 mg/5 ml [c]. 
Tablet: 10 mg (hydrochloride). 
a
Not in neonates. 
Injection: 2 mg base/ml in 2‐ml ampoule (as hydrochloride). 
Oral liquid: 4 mg base/5 ml. 
ondansetron a 
Solid oral dosage form: Eq 4 mg base; Eq 8 mg base; Eq 24 mg 
base. 
a
>1 month. 
17.3 Anti-inflammatory medicines
Retention enema. 
 sulfasalazine 
Suppository: 500 mg. 
Tablet: 500 mg. 
Complementary List 
Retention enema. 
 hydrocortisone 
Suppository: 25 mg (acetate). 
(the   only applies to hydrocortisone retention enema). 
17.4 Laxatives
 senna
EML 17 (March 2011)
 
Tablet: 7.5 mg (sennosides) (or traditional dosage forms). 
page - 24
Essential Medicines 
WHO Model List 
17th edition 
17.5 Medicines used in diarrhoea
17.5.1 Oral rehydration
oral rehydration salts 
glucose:  
 
 
sodium:  
 
 
chloride:  
 
 
potassium:  
 
 
citrate:   
 
 
osmolarity:  
 
 
glucose:  
 
 
sodium chloride: 
 
potassium chloride: 
 
trisodium citrate dihydrate+: 
75 mEq  
75 mEq or mmol/L  
65 mEq or mmol/L 
20 mEq or mmol/L  
10 mmol/L  
245 mOsm/L  
13.5 g/L  
  2.6 g/L 
  1.5 g/L  
  2.9 g/L  
+ trisodium citrate dihydrate may be replaced by sodium 
hydrogen carbonate (sodium bicarbonate) 2.5 g/L. However, as the 
stability of this latter formulation is very poor under tropical 
conditions, it is only recommended when manufactured for 
immediate use.  
Powder for dilution in 200 ml; 500 ml; 1 L. 
17.5.2 Medicines for diarrhoea in children
Solid oral dosage form: 20 mg. 
zinc sulfate* 
* In acute diarrhoea zinc sulfate should be used as an adjunct to 
oral rehydration salts. 
18. HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES
18.1 Adrenal hormones and synthetic substitutes
fludrocortisone   Tablet: 100 micrograms (acetate). 
hydrocortisone   Tablet: 5 mg; 10 mg; 20 mg. 
18.2 Androgens
Complementary List 
testosterone 
Injection: 200 mg (enanthate) in 1‐ml ampoule. 
18.3 Contraceptives
18.3.1 Oral hormonal contraceptives
 ethinylestradiol +   levonorgestrel   Tablet: 30 micrograms + 150 micrograms. 
 ethinylestradiol +   norethisterone   Tablet: 35 micrograms + 1 mg. 
levonorgestrel
Tablet: 30 micrograms; 750 micrograms (pack of two); 1.5 mg. 
18.3.2 Injectable hormonal contraceptives
estradiol cypionate +  Injection: 5 mg + 25 mg. 
   medroxyprogesterone acetate   
medroxyprogesterone acetate  Depot injection: 150 mg/ml in 1‐ml vial. 
norethisterone enantate  Oily solution: 200 mg/ml in 1‐ml ampoule. 
EML 17 (March 2011)
 
page - 25
Essential Medicines 
WHO Model List 
17th edition 
18.3.3 Intrauterine devices
copper‐containing device 
18.3.4 Barrier methods
condoms 
diaphragms 
18.3.5 Implantable contraceptives
levonorgestrel‐releasing implant
Two‐rod levonorgestrel‐releasing implant, each rod containing 
75 mg of levonorgestrel (150 mg total).
18.4 Estrogens
18.5 Insulins and other medicines used for diabetes
glibenclamide  Tablet: 2.5 mg; 5 mg. 
glucagon  Injection: 1 mg/ml. 
insulin injection (soluble)  Injection: 40 IU/ml in 10‐ml vial; 100 IU/ml in 10‐ml vial.  
intermediate‐acting insulin   Injection: 40 IU/ml in 10‐ml vial; 100 IU/ml in 10‐ml vial  
                                                  (as compound insulin zinc suspension or isophane insulin). 
metformin  Tablet: 500 mg (hydrochloride). 
Complementary List [c] 
metformin  
Tablet: 500 mg (hydrochloride). 
18.6 Ovulation inducers 
Complementary List 
clomifene 
Tablet: 50 mg (citrate). 
18.7 Progestogens 
 medroxyprogesterone acetate 
Tablet: 5 mg. 
18.8 Thyroid hormones and antithyroid medicines 
levothyroxine  Tablet: 25 micrograms [c]; 50 micrograms; 100 micrograms 
                       (sodium salt). 
potassium iodide  Tablet: 60 mg. 
 propylthiouracil 
Tablet: 50 mg. 
Complementary List [c] 
Lugolʹs solution  Oral liquid: about 130 mg total iodine/ml. 
potassium iodide  Tablet: 60 mg. 
propylthiouracil   Tablet: 50 mg. 
EML 17 (March 2011)
 
page - 26
Essential Medicines 
WHO Model List 
17th edition 
19. IMMUNOLOGICALS
19.1 Diagnostic agents
All tuberculins should comply with the WHO Requirements for Tuberculins (Revised 1985). WHO Expert 
Committee on Biological Standardization. Thirty‐sixth report. (WHO Technical Report Series, No. 745, 
1987, Annex 1).  
tuberculin, purified protein derivative 
Injection. 
(PPD) 
19.2 Sera and immunoglobulins
All plasma fractions should comply with the WHO Requirements for the Collection, Processing and 
Quality Control of Blood, Blood Components and Plasma Derivatives (Revised 1992). WHO Expert 
Committee on Biological Standardization. Forty‐third report. (WHO Technical Report Series, No. 840, 1994, 
Annex 2). 
anti‐D immunoglobulin (human) 
Injection: 250 micrograms in single‐dose vial. 
antitetanus immunoglobulin (human)  Injection: 500 IU in vial. 
Injection. 
antivenom immunoglobulin* 
* Exact type to be defined locally. 
diphtheria antitoxin 
 rabies immunoglobulin 
Injection: 10 000 IU; 20 000 IU in vial. 
Injection: 150 IU/ml in vial. 
19.3 Vaccines
Selection of vaccines from the Model List will need to be determined by each country after consideration of 
international  recommendations,  epidemiology  and  national  priorities.  The  list  below  details  the  vaccines 
for which there is either a recommendation from the Strategic Advisory Group of Experts on Immunization 
(SAGE)  (http://www.who.int/immunization/sage_conclusions/en/index.html)  and/or  a  WHO  position 
paper  (http://www.who.int/immunization/documents/positionpapers/en/index.html).  This  site  will  be 
updated  as  new  position  papers  are  published  and  contains  the  most  recent  information  and 
recommendations. 
All vaccines should comply with the WHO Requirements for Biological Substances. 
BCG vaccine   
cholera vaccine   
diphtheria vaccine   
hepatitis A vaccine   
hepatitis B vaccine   
Haemophilus influenzae type b vaccine   
influenza vaccine   
Japanese encephalitis vaccine   
measles vaccine   
meningococcal meningitis vaccine   
mumps vaccine    
EML 17 (March 2011)
 
page - 27
Essential Medicines 
WHO Model List 
17th edition 
pertussis vaccine   
pneumococcal vaccine   
poliomyelitis vaccine    
rabies vaccine    
rotavirus vaccine   
rubella vaccine    
tetanus vaccine    
typhoid vaccine    
varicella vaccine   
yellow fever vaccine   
20. MUSCLE RELAXANTS (PERIPHERALLY-ACTING) AND CHOLINESTERASE
INHIBITORS
The Expert Committee has requested a review of this section at its next meeting. 
 atracurium  
neostigmine 
Injection: 10 mg/ml (atracurium besylate). 
Injection: 500 micrograms in 1‐ml ampoule; 2.5 mg (metilsulfate) 
in 1‐ml ampoule. 
Tablet: 15 mg (bromide). 
Injection: 50 mg (chloride)/ml in 2‐ml ampoule. 
suxamethonium 
Powder for injection (chloride), in vial. 
 vecuronium [c] 
Powder for injection: 10 mg (bromide) in vial. 
Complementary List 
Injection: 1 mg in 1‐ml ampoule. 
pyridostigmine 
Tablet: 60 mg (bromide). 
 vecuronium 
Powder for injection: 10 mg (bromide) in vial. 
21. OPHTHALMOLOGICAL PREPARATIONS
This section will be reviewed at the next meeting of the Expert Committee. 
21.1 Anti-infective agents
aciclovir 
Ointment: 3% W/W. 
 gentamicin Solution (eye drops): 0.3% (sulfate). 
 tetracycline Eye ointment: 1% (hydrochloride). 
21.2 Anti-inflammatory agents 
 prednisolone
Solution (eye drops): 0.5% (sodium phosphate). 
 
 
 
EML 17 (March 2011)
 
page - 28
Essential Medicines 
WHO Model List 
17th edition 
21.3 Local anaesthetics 
Solution (eye drops): 0.5% (hydrochloride). 
 tetracaine a
a
Not in preterm neonates. 
21.4 Miotics and antiglaucoma medicines 
acetazolamide 
Tablet: 250 mg. 
 pilocarpine  Solution (eye drops): 2%; 4% (hydrochloride or nitrate). 
 timolol  Solution (eye drops): 0.25%; 0.5% (as hydrogen maleate). 
21.5 Mydriatics
Solution (eye drops): 0.1%; 0.5%; 1% (sulfate). 
atropine*  a  
* [c] Or homatropine (hydrobromide) or cyclopentolate 
(hydrochloride). 
a
>3 months. 
Complementary List 
epinephrine (adrenaline) 
Solution (eye drops): 2% (as hydrochloride). 
22. OXYTOCICS AND ANTIOXYTOCICS
22.1 Oxytocics
 ergometrine 
misoprostol
Injection: 200 micrograms (hydrogen maleate) in 1‐ml ampoule.  
Tablet: 200 micrograms.* 
* For management of incomplete abortion and miscarriage, and for 
prevention of postpartum haemorrhage where oxytocin is not 
available or cannot be safely used. 
Vaginal tablet: 25 micrograms.* 
* Only for use for induction of labour where appropriate facilities 
are available. 
oxytocin
Injection: 10 IU in 1‐ml. 
Complementary List 
mifepristone* – misoprostol* 
Where permitted under national 
law and where culturally 
acceptable. 
Tablet 200 mg – tablet 200 micrograms. 
* Requires close medical supervision. 
 
22.2 Antioxytocics (tocolytics)
nifedipine 
Immediate‐release capsule: 10 mg. 
23. PERITONEAL DIALYSIS SOLUTION
Complementary List 
intraperitoneal dialysis solution 
(of appropriate composition) 
EML 17 (March 2011)
 
Parenteral solution. 
page - 29
Essential Medicines 
WHO Model List 
17th edition 
24. MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDERS
24.1 Medicines used in psychotic disorders
Injection: 25 mg (hydrochloride)/ml in 2‐ml ampoule. 
 chlorpromazine 
Oral liquid: 25 mg (hydrochloride)/5 ml. 
Tablet: 100 mg (hydrochloride). 
 fluphenazine 
Injection: 25 mg (decanoate or enantate) in 1‐ml ampoule. 
Injection: 5 mg in 1‐ml ampoule. 
 haloperidol 
Tablet: 2 mg; 5 mg. 
Complementary List [c]
Injection: 25 mg (hydrochloride)/ml in 2‐ml ampoule. 
chlorpromazine
Oral liquid: 25 mg (hydrochloride)/5 ml. 
Tablet: 10 mg; 25 mg; 50 mg; 100 mg (hydrochloride). 
Injection: 5 mg in 1‐ml ampoule. 
haloperidol
Oral liquid: 2 mg/ml. 
Solid oral dosage form: 0.5 mg; 2 mg; 5 mg. 
24.2 Medicines used in mood disorders 
24.2.1 Medicines used in depressive disorders 
 amitriptyline
fluoxetine 
Tablet: 25 mg (hydrochloride). 
Solid oral dosage form: 20 mg (as hydrochloride). 
Complementary List [c] 
fluoxetine a
Solid oral dosage form: 20 mg (as hydrochloride). 
a
>8 years. 
24.2.2 Medicines used in bipolar disorders 
carbamazepine Tablet (scored): 100 mg; 200 mg. 
lithium carbonate Solid oral dosage form: 300 mg. 
valproic acid (sodium valproate) Tablet (enteric‐coated): 200 mg; 500 mg (sodium valproate). 
24.3 Medicines for anxiety disorders  
 diazepam
Tablet (scored): 2 mg; 5 mg. 
24.4 Medicines used for obsessive compulsive disorders 
clomipramine
Capsule: 10 mg; 25 mg (hydrochloride). 
24.5 Medicines for disorders due to psychoactive substance use 
nicotine replacement therapy (NRT)  
Chewing gum: 2 mg; 4 mg (as polacrilax). 
Transdermal patch: 5 mg to 30 mg/16 hrs; 7 mg to 21 mg/24 hrs. 
 
EML 17 (March 2011)
 
page - 30
Essential Medicines 
WHO Model List 
17th edition 
Complementary List 
Concentrate for oral liquid: 5 mg/ml; 10 mg/ml (hydrochloride). 
 methadone* 
Oral liquid: 5 mg/5 ml; 10 mg/5 ml (hydrochloride). 
* The square box is added to include buprenorphine. The medicines 
should only be used within an established support programme. 
25. MEDICINES ACTING ON THE RESPIRATORY TRACT 
25.1 Antiasthmatic and medicines for chronic obstructive pulmonary disease 
 beclometasone  Inhalation (aerosol): 50 micrograms (dipropionate) per dose; 
                        100 micrograms (dipropionate) per dose (as CFC free forms). 
 budesonide [c] Inhalation (aerosol): 100 micrograms per dose; 200 micrograms 
                         per dose. 
epinephrine (adrenaline)  Injection: 1 mg (as hydrochloride or hydrogen tartrate) in  
                                     1‐ml ampoule. 
ipratropium bromide  Inhalation (aerosol): 20 micrograms/metered dose. 
Inhalation (aerosol): 100 micrograms (as sulfate) per dose. 
Injection: 50 micrograms (as sulfate)/ml in 5‐ml ampoule. 
 salbutamol 
Metered dose inhaler (aerosol): 100 micrograms (as sulfate) per 
dose. 
Respirator solution for use in nebulizers: 5 mg (as sulfate)/ml. 
26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID-BASE
DISTURBANCES 
26.1 Oral 
oral rehydration salts   See section 17.5.1.  
potassium chloride  Powder for solution. 
26.2 Parenteral
glucose 
Injectable solution: 5% (isotonic); 10% (hypertonic);  
50% (hypertonic). 
Injectable solution: 4% glucose, 0.18% sodium chloride  
(equivalent to Na+ 30 mmol/L, Cl‐ 30 mmol/L). 
glucose with sodium chloride 
Injectable solution: 5% glucose, 0.9% sodium chloride (equivalent 
to 150 mmol/L Na+ and 150 mmol/L Cl‐); 5% glucose, 0.45% 
sodium chloride (equivalent to 75 mmol/L Na+ and 75 mmol/L  
Cl‐) [c]. 
Solution: 11.2% in 20‐ml ampoule 
(equivalent to K+ 1.5 mmol/ml, Cl‐ 1.5 mmol/ml). 
potassium chloride 
EML 17 (March 2011)
 
Solution for dilution: 7.5% (equivalent to K 1 mmol/ml and  
Cl 1 mmol/ml) [c]; 15% (equivalent to K 2 mmol/ml and  
Cl 2 mmol/ml) [c]. 
page - 31
Essential Medicines 
WHO Model List 
sodium chloride 
17th edition 
Injectable solution: 0.9% isotonic (equivalent to Na+ 154 mmol/L, 
Cl‐ 154 mmol/L). 
Injectable solution: 1.4% isotonic (equivalent to Na+ 167 mmol/L, 
HCO3‐ 167 mmol/L). 
sodium hydrogen carbonate 
Solution: 8.4% in 10‐ml ampoule (equivalent to Na+ 1000 mmol/L, 
HCO3‐1000 mmol/L). 
 sodium lactate, compound solution 
Injectable solution. 
26.3 Miscellaneous 
water for injection 
2‐ml; 5‐ml; 10‐ml ampoules. 
27. VITAMINS AND MINERALS 
ascorbic acid 
Tablet: 50 mg. 
Oral liquid: 400 IU/ml. 
cholecalciferol* [c]
Solid oral dosage form: 400 IU; 1000 IU. 
* Ergocalciferol can be used as an alternative. 
Oral liquid: 250 micrograms/ml (10 000 IU/ml). 
 ergocalciferol 
Solid oral dosage form: 1.25 mg (50 000 IU). 
Capsule: 200 mg. 
iodine  
 nicotinamide 
pyridoxine 
Iodized oil: 1 ml (480 mg iodine); 0.5 ml (240 mg iodine) in 
ampoule (oral or injectable); 0.57 ml (308 mg iodine) in dispenser 
bottle. 
Tablet: 50 mg. 
Tablet: 25 mg (hydrochloride). 
Capsule: 50 000 IU; 100 000 IU; 200 000 IU (as palmitate). 
retinol 
Oral oily solution: 100 000 IU (as palmitate)/ml in multidose 
dispenser. 
Tablet (sugar‐coated): 10 000 IU (as palmitate). 
Water‐miscible injection: 100 000 IU (as palmitate) in  
2‐ml ampoule. 
riboflavin  Tablet: 5 mg. 
sodium fluoride  In any appropriate topical formulation. 
thiamine  Tablet: 50 mg (hydrochloride). 
Complementary List 
calcium gluconate 
Injection: 100 mg/ml in 10‐ml ampoule. 
28. EAR, NOSE AND THROAT CONDITIONS IN CHILDREN [c] 
acetic acid 
Topical: 2%, in alcohol. 
budesonide   Nasal spray: 100 micrograms per dose. 
ciprofloxacin  Topical: 0.3% drops (as hydrochloride). 
EML 17 (March 2011)
 
page - 32
Essential Medicines 
WHO Model List 
17th edition 
Nasal spray: 0.05%.  
xylometazoline a  
a Not in children less than 3 months. 
29. SPECIFIC MEDICINES FOR NEONATAL CARE [c] 
caffeine citrate
Injection: 20 mg/ml (equivalent to 10 mg caffeine base/ml). 
Oral liquid: 20 mg/ml (equivalent to 10 mg caffeine base/ml). 
Complementary List 
 ibuprofen 
Solution for injection: 5 mg/ml. 
Solution for injection:  
 prostaglandin E 
surfactant 
Prostaglandin E1: 0.5 mg/ml in alcohol. 
Prostaglandin E2: 1 mg/ml. 
Suspension for intratracheal instillation: 25 mg/ml or 80 mg/ml. 
 
EML 17 (March 2011)
 
page - 33
Essential Medicines 
WHO Model List 
17th edition 
Table 1: Medicines with age or weight restrictions
atazanavir 
atropine 
benzyl benzoate 
betamethasone topical preparations 
cefazolin 
ceftriaxone 
chlorphenamine 
diloxanide 
doxycycline 
efavirenz 
emtricitabine 
fluoxetine 
ibuprofen 
mefloquine 
metoclopramide 
ondansetron 
saquinavir 
silver sulfadiazine 
tetracaine 
trimethoprim 
xylometazoline 
 
>25 kg 
>3 months 
>2 years 
Hydrocortisone preferred in neonates 
>1 month 
>41 weeks corrected gestational age 
>1 year 
>25 kg  
>8 years (except for serious infections e.g. cholera) 
>3 years or >10 kg  
>3 months 
>8 years 
>3 months (except IV form for patent ductus arteriosus) 
>5 kg or >3 months 
Not in neonates 
>1 month 
>25 kg  
>2 months 
Not in preterm neonates 
>6 months 
>3 months 
 
 
 
 
 
 
 
 
 
 
EML 17 (March 2011)
 
page - 34
Essential Medicines 
WHO Model List 
17th edition 
Annex 1: Explanation of dosage forms
 
A. Principal dosage forms used in EML - Oral administration
 
 
Term 
 
Solid oral dosage form 
Tablets  
Tablets (qualified) 
 
Definition 
 
Refers to tablets or capsules or other solid dosage forms such as ʹmeltsʹ 
that are immediate‐release preparations. It implies that there is no 
difference in clinical efficacy or safety between the available dosage 
forms, and countries should therefore choose the form(s) to be listed 
depending on quality and availability.   
 
The term ʹsolid oral dosage formʹ is never intended to allow any type of 
modified‐release tablet. 
 
Refers to:  
 
• uncoated or coated (film‐coated or sugar‐coated) tablets that are 
intended to be swallowed whole;  
•
•
•
unscored and scored*;  
tablets that are intended to be chewed before being swallowed;  
tablets that are intended to be dispersed or dissolved in water or 
another suitable liquid before being swallowed;  
tablets that are intended to be crushed before being swallowed. 
•
 
The term ʹtabletʹ without qualification is never intended to allow any 
type of modified‐release tablet. 
 
Refers to a specific type of tablet: 
chewable ‐ tablets that are intended to be chewed before being 
swallowed;  
dispersible ‐ tablets that are intended to be dispersed in water or 
another suitable liquid before being swallowed;  
soluble ‐ tablets that are intended to be dissolved in water or another 
suitable liquid before being swallowed;  
crushable ‐ tablets that are intended to be crushed before being 
swallowed;  
scored ‐ tablets bearing a break mark or marks where sub‐division is 
intended in order to provide doses of less than one tablet; 
sublingual ‐ tablets that are intended to be placed beneath the tongue. 
 
The term ʹtabletʹ is always qualified with an additional term (in 
parentheses) in entries where one of the following types of tablet is 
intended: gastro‐resistant (such tablets may sometimes be described as 
enteric‐coated or as delayed‐release), prolonged‐release or another 
modified‐release form. 
 
 
                                                           
*
  
Scored tablets may be divided for ease of swallowing, provided dose is a whole number of tablets. 
EML 17 (March 2011)
 
page - 35
Essential Medicines 
WHO Model List 
 
Term 
 
Capsules  
Capsules (qualified) 
Granules 
Oral powder 
Oral liquid  
17th edition 
 
Definition 
 
Refers to hard or soft capsules.  
 
The term ʹcapsuleʹ without qualification is never intended to allow any 
type of modified‐release capsule. 
 
The term ʹcapsuleʹ with qualification refers to gastro‐resistant (such 
capsules may sometimes be described as enteric‐coated or as delayed‐
release), prolonged‐release  or another modified‐release form. 
 
Preparations that are issued to patient as granules to be swallowed 
without further preparation, to be chewed, or to be taken in or with 
water or another suitable liquid. 
 
The term ʹgranulesʹ without further qualification is never intended to 
allow any type of modified‐release granules. 
 
Preparations that are issued to patient as powder (usually as single‐
dose) to be taken in or with water or another suitable liquid. 
 
Liquid preparations intended to be swallowed i.e. oral solutions, 
suspensions, emulsions and oral drops, including those constituted from 
powders or granules, but not those preparations intended for oromucosal 
administration e.g. gargles and mouthwashes. 
 
Oral liquids presented as powders or granules may offer benefits in the 
form of better stability and lower transport costs. If more than one type 
of oral liquid is available on the same market (e.g. solution, suspension, 
granules for reconstitution), they may be interchanged and in such cases 
should be bioequivalent. It is preferable that oral liquids do not contain 
sugar and that solutions for children do not contain alcohol. 
 
 
B. Principal dosage forms used in EMLc - Parenteral administration
 
Term 
Injection 
Injection (qualified) 
Injection (oily) 
Intravenous infusion 
Definition 
Refers to solutions, suspensions and emulsions including those 
constituted from powders or concentrated solutions. 
Route of administration is indicated in parentheses where relevant. 
The term injection is qualified by (oily) in relevant entries. 
Refers to solutions and emulsions including those constituted from 
powders or concentrated solutions. 
 
EML 17 (March 2011)
 
page - 36
Essential Medicines 
WHO Model List 
17th edition 
C. Other dosage forms
 
Mode of 
administration 
To the eye 
Topical 
Rectal  
Vaginal 
Inhalation 
Term to be used 
Eye drops, eye ointments. 
For liquids: lotions, paints. 
For semi‐solids: cream, ointment. 
Suppositories, gel or solution. 
Pessaries or vaginal tablets. 
Powder for inhalation, pressurized inhalation, nebulizer. 
 
EML 17 (March 2011)
 
page - 37
Essential Medicines 
WHO Model List 
17th edition 
Index 
abacavir (ABC) ........................................................ 10 
acetazolamide.......................................................... 29 
acetic acid................................................................. 32 
acetylcysteine ............................................................ 3 
acetylsalicylic acid ........................................ 2, 15, 21 
aciclovir .............................................................. 10, 28 
albendazole................................................................ 5 
allopurinol ........................................................... 2, 16 
amidotrizoate .......................................................... 22 
amikacin....................................................................... 9 
amiloride .................................................................. 23 
amiodarone ................................................................ 20 
amitriptyline ...................................................... 17, 30 
amlodipine............................................................... 20 
amodiaquine............................................................ 13 
amoxicillin ................................................................. 5 
amoxicillin + clavulanic acid ................................... 5 
amphotericin B..................................................... 10, 13 
ampicillin ................................................................... 5 
anti‐D immunoglobulin (human) ......................... 27 
antitetanus immunoglobulin (human)................. 27 
antivenom immunoglobulin ................................. 27 
artemether................................................................ 13 
artemether + lumefantrine ..................................... 13 
artesunate................................................................. 13 
artesunate + amodiaquine...................................... 14 
ascorbic acid ............................................................ 32 
asparaginase............................................................... 16 
atazanavir................................................................. 11 
atracurium ............................................................... 28 
atropine ............................................................ 1, 3, 29 
azathioprine ........................................................... 3, 16 
azithromycin.............................................................. 7 
barium sulfate ................................................... 22, 23 
BCG vaccine............................................................. 27 
beclometasone ......................................................... 31 
benzathine benzylpenicillin .................................... 6 
benznidazole............................................................ 15 
benzoyl peroxide..................................................... 22 
benzyl benzoate....................................................... 22 
benzylpenicillin......................................................... 6 
betamethasone......................................................... 22 
biperiden .................................................................. 18 
bisoprolol ........................................................... 20, 21 
bleomycin................................................................... 16 
budesonide ........................................................ 31, 32 
bupivacaine................................................................ 1 
caffeine citrate ......................................................... 33 
calamine ................................................................... 22 
calcium folinate.......................................................... 16 
EML 17 (March 2011)
 
calcium gluconate ............................................... 3, 32 
capreomycin ................................................................. 9 
carbamazepine..................................................... 4, 30 
carboplatin ................................................................. 16 
cefalexin...................................................................... 6 
cefazolin...................................................................... 6 
cefixime....................................................................... 6 
cefotaxime .................................................................... 6 
ceftazidime ................................................................... 6 
ceftriaxone.................................................................. 6 
charcoal, activated..................................................... 3 
chlorambucil............................................................... 16 
chloramphenicol........................................................ 7 
chlorhexidine ........................................................... 23 
chlorine base compound ........................................ 23 
chloroquine .......................................................... 2, 14 
chloroxylenol ........................................................... 23 
chlorphenamine......................................................... 3 
chlorpromazine ....................................................... 30 
cholecalciferol .......................................................... 32 
cholera vaccine ........................................................ 27 
ciclosporin.................................................................. 16 
ciprofloxacin ........................................................ 7, 32 
clarithromycin ........................................................... 7 
clindamycin ................................................................. 8 
clofazimine................................................................. 8 
clomifene .................................................................... 26 
clomipramine........................................................... 30 
clotrimazole ............................................................... 9 
cloxacillin ................................................................... 6 
coal tar ...................................................................... 22 
codeine........................................................................ 2 
condoms ................................................................... 26 
copper‐containing device....................................... 26 
cyclizine.................................................................... 17 
cyclophosphamide ...................................................... 16 
cycloserine.................................................................... 9 
cytarabine................................................................... 16 
dacarbazine ................................................................ 16 
dactinomycin.............................................................. 16 
dapsone ...................................................................... 8 
daunorubicin.............................................................. 16 
deferoxamine .......................................................... 4, 19 
dexamethasone.............................................. 3, 17, 24 
dextran 70................................................................. 19 
diaphragms .............................................................. 26 
diazepam........................................................ 4, 17, 30 
didanosine (ddI) ...................................................... 10 
diethylcarbamazine .................................................. 5 
digoxin................................................................ 20, 21 
page - 38
Essential Medicines 
WHO Model List 
diloxanide ................................................................ 13 
dimercaprol .................................................................. 4 
diphtheria antitoxin................................................ 27 
diphtheria vaccine .................................................. 27 
dithranol................................................................... 22 
docetaxel .................................................................... 16 
docusate sodium ..................................................... 18 
dopamine.................................................................... 21 
doxorubicin................................................................ 16 
doxycycline.......................................................... 7, 14 
efavirenz (EFV or EFZ)........................................... 11 
efavirenz + emtricitabine + tenofovir ................... 12 
eflornithine .............................................................. 15 
emtricitabine (FTC)................................................. 11 
emtricitabine + tenofovir........................................ 12 
enalapril ............................................................. 20, 21 
ephedrine...................................................................... 1 
epinephrine (adrenaline) ....................... 3, 20, 29, 31 
ergocalciferol ........................................................... 32 
ergometrine.............................................................. 29 
erythromycin ............................................................. 7 
estradiol cypionate + medroxyprogesterone 
acetate................................................................... 25 
ethambutol................................................................. 8 
ethambutol + isoniazid............................................. 8 
ethambutol + isoniazid + pyrazinamide + 
rifampicin............................................................... 8 
ethambutol + isoniazid + rifampicin....................... 8 
ethanol...................................................................... 23 
ethinylestradiol + levonorgestrel .......................... 25 
ethinylestradiol + norethisterone.......................... 25 
ethionamide.................................................................. 9 
ethosuximide................................................................ 4 
etoposide .................................................................... 16 
factor IX complex (coagulation factors, II, VII,  
IX, X) concentrate ................................................. 19 
factor VIII concentrate............................................... 19 
ferrous salt ............................................................... 18 
ferrous salt + folic acid ........................................... 18 
fluconazole................................................................. 9 
flucytosine.................................................................. 10 
fludrocortisone ........................................................ 25 
fluorescein................................................................ 22 
fluorouracil .......................................................... 16, 22 
fluoxetine ........................................................... 18, 30 
fluphenazine............................................................ 30 
folic acid ................................................................... 18 
furosemide ......................................................... 21, 23 
gentamicin ........................................................... 7, 28 
glibenclamide .......................................................... 26 
glucagon................................................................... 26 
glucose...................................................................... 31 
EML 17 (March 2011)
 
17th edition 
glucose with sodium chloride ............................... 31 
glutaral...................................................................... 23 
glyceryl trinitrate..................................................... 20 
griseofulvin .............................................................. 10 
Haemophilus influenzae type b vaccine .................. 27 
haloperidol............................................................... 30 
halothane.................................................................... 1 
heparin sodium ....................................................... 19 
hepatitis A vaccine.................................................. 27 
hepatitis B vaccine................................................... 27 
human normal immunoglobulin................................ 19 
hydralazine .............................................................. 20 
hydrochlorothiazide ................................... 20, 21, 23 
hydrocortisone................................... 3, 17, 22, 24, 25 
hydroxocobalamin .................................................. 18 
hydroxycarbamide................................................ 16, 19 
hydroxychloroquine ..................................................... 3 
hyoscine hydrobromide ......................................... 18 
ibuprofen.................................................. 2, 15, 18, 33 
ifosfamide ................................................................... 16 
imipenem + cilastatin................................................... 7 
indinavir (IDV) ........................................................ 11 
influenza vaccine..................................................... 27 
insulin injection (soluble)....................................... 26 
intermediate‐acting insulin.................................... 26 
intraperitoneal dialysis solution 
(of appropriate composition) .................................. 29 
iodine ........................................................................ 32 
iohexol ...................................................................... 23 
ipratropium bromide.............................................. 31 
isoflurane.................................................................... 1 
isoniazid ..................................................................... 8 
isoniazid + pyrazinamide + rifampicin .................. 9 
isoniazid + rifampicin ............................................... 9 
isosorbide dinitrate ................................................. 20 
ivermectin .................................................................. 5 
Japanese encephalitis vaccine................................ 27 
kanamycin.................................................................... 9 
ketamine ..................................................................... 1 
lactulose.................................................................... 18 
lamivudine (3TC) .................................................... 11 
lamivudine + nevirapine + stavudine................... 12 
lamivudine + nevirapine + zidovudine ................ 12 
lamivudine + zidovudine....................................... 12 
levamisole .................................................................. 5 
levodopa + carbidopa ............................................. 18 
levonorgestrel .......................................................... 25 
levonorgestrel‐releasing implant .......................... 26 
levothyroxine........................................................... 26 
lidocaine ............................................................... 1, 20 
lidocaine + epinephrine (adrenaline)...................... 1 
lithium carbonate .................................................... 30 
page - 39
Essential Medicines 
WHO Model List 
lopinavir + ritonavir (LPV/r) ................................. 11 
lorazepam .................................................................. 4 
Lugolʹs solution......................................................... 26 
magnesium sulfate.................................................... 4 
mannitol ................................................................... 23 
measles vaccine ....................................................... 27 
mebendazole.............................................................. 5 
medroxyprogesterone acetate ......................... 25, 26 
mefloquine ............................................................... 14 
meglumine iotroxate .................................................. 23 
melarsoprol.............................................................. 15 
meningococcal meningitis vaccine ....................... 27 
mercaptopurine.......................................................... 16 
mesna......................................................................... 17 
metformin ................................................................ 26 
methadone.................................................................. 31 
methotrexate .......................................................... 3, 17 
methyldopa.............................................................. 21 
methylprednisolone.................................................... 17 
methylthioninium chloride (methylene blue)....... 3 
metoclopramide ...................................................... 24 
metronidazole ..................................................... 7, 13 
miconazole............................................................... 21 
midazolam ........................................................... 1, 18 
mifepristone ............................................................... 29 
miltefosine ............................................................... 13 
misoprostol .............................................................. 29 
morphine.......................................................... 1, 2, 18 
mumps vaccine ....................................................... 27 
mupirocin................................................................. 22 
naloxone ..................................................................... 3 
neostigmine ............................................................. 28 
nevirapine (NVP).................................................... 11 
niclosamide................................................................ 5 
nicotinamide............................................................ 32 
nicotine replacement therapy (NRT).................... 30 
nifedipine ................................................................. 29 
nifurtimox ................................................................ 15 
nitrofurantoin ............................................................ 8 
nitrous oxide.............................................................. 1 
norethisterone enantate.......................................... 25 
nystatin..................................................................... 10 
ofloxacin....................................................................... 9 
omeprazole .............................................................. 24 
ondansetron....................................................... 18, 24 
oral rehydration salts ....................................... 25, 31 
oseltamivir ............................................................... 12 
oxamniquine ................................................................ 5 
oxygen ........................................................................ 1 
oxytocin.................................................................... 29 
paclitaxel.................................................................... 17 
p‐aminosalicylic acid ................................................... 9 
EML 17 (March 2011)
 
17th edition 
pancreatic enzymes .................................................... 23 
paracetamol.......................................................... 2, 15 
paromomycin........................................................... 13 
penicillamine................................................................ 3 
pentamidine ............................................................... 15 
permethrin ............................................................... 22 
pertussis vaccine ..................................................... 28 
phenobarbital............................................................. 4 
phenoxymethylpenicillin ......................................... 6 
phenytoin ................................................................... 4 
phytomenadione ..................................................... 19 
pilocarpine ............................................................... 29 
pneumococcal vaccine............................................ 28 
podophyllum resin ................................................. 22 
poliomyelitis vaccine .............................................. 28 
polyvidone iodine ................................................... 23 
potassium chloride.................................................. 31 
potassium ferric hexacyano‐ferrate(II) ‐2H20 
(Prussian blue)....................................................... 3 
potassium iodide .................................................. 10, 26 
potassium permanganate....................................... 22 
praziquantel............................................................... 5 
prednisolone .................................................. 3, 17, 28 
primaquine............................................................... 14 
procaine benzylpenicillin......................................... 6 
procarbazine............................................................... 17 
proguanil.................................................................. 14 
propofol ...................................................................... 1 
propranolol .............................................................. 16 
propylthiouracil ...................................................... 26 
prostaglandin E.......................................................... 33 
protamine sulfate .................................................... 19 
pyrantel ...................................................................... 5 
pyrazinamide............................................................. 9 
pyridostigmine ........................................................... 28 
pyridoxine ................................................................ 32 
pyrimethamine ........................................................ 14 
quinine...................................................................... 14 
rabies immunoglobulin .......................................... 27 
rabies vaccine........................................................... 28 
ranitidine .................................................................. 24 
retinol........................................................................ 32 
ribavirin.................................................................... 12 
riboflavin .................................................................. 32 
rifabutin...................................................................... 9 
rifampicin ............................................................... 8, 9 
ritonavir.................................................................... 12 
rotavirus vaccine ..................................................... 28 
rubella vaccine......................................................... 28 
salbutamol................................................................ 31 
salicylic acid............................................................. 22 
saquinavir (SQV)..................................................... 12 
page - 40
Essential Medicines 
WHO Model List 
17th edition 
terbinafine ................................................................ 21 
testosterone ................................................................ 25 
tetanus vaccine ........................................................ 28 
tetracaine .................................................................. 29 
tetracycline ............................................................... 28 
thiamine.................................................................... 32 
thioguanine ................................................................ 17 
timolol....................................................................... 29 
tranexamic acid ....................................................... 19 
triclabendazole .......................................................... 5 
trimethoprim ............................................................. 8 
tropicamide .............................................................. 22 
tuberculin, purified protein derivative (PPD)..... 27 
typhoid vaccine ....................................................... 28 
urea ........................................................................... 22 
valproic acid (sodium valproate)...................... 4, 30 
vancomycin .................................................................. 8 
varicella vaccine ...................................................... 28 
vecuronium.............................................................. 28 
verapamil ................................................................. 20 
vinblastine.................................................................. 17 
vincristine .................................................................. 17 
warfarin .................................................................... 19 
water for injection ................................................... 32 
xylometazoline ........................................................ 33 
yellow fever vaccine ............................................... 28 
zidovudine (ZDV or AZT) ..................................... 11 
zinc sulfate ............................................................... 25 
selenium sulfide ...................................................... 21 
senna................................................................... 18, 24 
silver sulfadiazine................................................... 22 
simvastatin............................................................... 21 
sodium calcium edetate................................................ 4 
sodium chloride ...................................................... 32 
sodium fluoride....................................................... 32 
sodium hydrogen carbonate ................................. 32 
sodium lactate ......................................................... 32 
sodium nitrite ............................................................ 3 
sodium nitroprusside................................................. 21 
sodium stibogluconate or  
meglumine antimoniate ..................................... 13 
sodium thiosulfate .............................................. 4, 21 
spectinomycin ........................................................... 8 
spironolactone ......................................................... 23 
stavudine (d4T) ....................................................... 11 
streptokinase .............................................................. 21 
streptomycin.............................................................. 9 
succimer....................................................................... 4 
sulfadiazine.............................................................. 14 
sulfadoxine + pyrimethamine ............................... 14 
sulfamethoxazole + trimethoprim .................... 8, 15 
sulfasalazine........................................................... 3, 24 
suramin sodium ...................................................... 15 
surfactant................................................................... 33 
suxamethonium ...................................................... 28 
tamoxifen ................................................................... 17 
tenofovir disoproxil fumarate ............................... 11 
 
EML 17 (March 2011)
 
page - 41
